Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open‐label, randomized verification study

Yoshida, Yukie; Hirama, Akio; Hashimoto, Kazumasa; Satô, Takeshi; Yokota, Noritsugu; Saeki, Hidehisa; Kishida, Momoyo; Nakamura, Hiroshi; Kanakubo, Akira; Tsuruoka, Shuichi

doi:10.1111/1346-8138.15950

Cited by 6 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a few mild skin inflammatory reactions were reported in the MPS cream groups, such as erythema, burning, and tingling at the application site. Many clinical trials also had the same results that no systematic AEs were related to the MPS cream (46,47). With regard to the incidence of skin inflammatory reactions, MPS cream was comparable to vaseline ointment and was superior to urea cream.…”

Section: Discussionmentioning

confidence: 74%

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream for Non-Exudative Eczema: A Systematic Review and Meta-Analysis

Xiang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Background: Mucopolysaccharide polysulfate (MPS) cream as a moisturizer is widely applied to treat eczema, and a lot of clinical trials have demonstrated its efficacy and safety. However, there is no further research to collect and analyze these studies.Objective: This meta-analysis aimed to assess the efficacy and safety of MPS cream as monotherapy or add-on therapy for non-exudative eczema.Methods: Ten databases were searched to identify the eligible randomized controlled trials (RCTs) from their inception to July 31, 2021. Revman 5.3 software was used for the meta-analysis.Results: A total of eligible 20 studies were included. Among the 20 studies, 2 studies compared MPS cream with other moisturizers, 14 compared MPS cream plus topical corticosteroids (TCS) with TCS alone, and 4 compared with MPS cream plus tacrolimus ointment with tacrolimus ointment alone. The pooled results demonstrated that MPS cream had a higher total efficacy rate [Risk ratio (RR) 1.21, 95% CI: 1.12 to 1.30, P < 0.00001], a lower recurrence rate (RR 0.44, 95% CI: 0.26 to 0.74, P = 0.002) and a lower pruritus score [mean difference (MD) −1.78, 95% CI: −2.16 to −1.40, P < 0.00001] than urea cream or vaseline ointment. Moreover, in comparison with TCS or tacrolimus ointment alone, the combination treatment performed better in terms of total efficacy rate, total symptom score, recurrence rate, and pruritus score. For safety, the skin adverse events were mild, and MPS cream as monotherapy or add-on therapy did not increase the risk of skin adverse events.Conclusions: MPS cream as monotherapy or add-on therapy could provide a good effect for treating non-exudative eczema with mild and tolerable skin adverse events. However, due to the suboptimal quality of the included studies, high-quality and large-sample RCTs are needed in the future for update or validation.Systematic Review Registration: PROSPERO (https://www.crd.york.ac.uk/PROSPERO/), identifier: CRD42021265735.

show abstract

Section: Discussionmentioning

confidence: 74%

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream for Non-Exudative Eczema: A Systematic Review and Meta-Analysis

Xiang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Concerning dialysis, the baseline scores for dryness, pruritus, insomnia, and DLQI are close to the data in the literature. 11 , 12 Four previous studies demonstrated the efficacy of an emollient in xerosis and uremic pruritus, 7 , 8 , 31 , 32 but only one evaluated the skin-related quality of life. 32 Interestingly, uremic pruritus affected the quality of life of patients with end-stage renal disease, 11 , 12 but not xerosis (evaluated by the El Gammal index), corresponding more to a prognostic factor for worsening of the skin-related quality of life.…”

Section: Discussionmentioning

confidence: 99%

“… 11 , 12 Four previous studies demonstrated the efficacy of an emollient in xerosis and uremic pruritus, 7 , 8 , 31 , 32 but only one evaluated the skin-related quality of life. 32 Interestingly, uremic pruritus affected the quality of life of patients with end-stage renal disease, 11 , 12 but not xerosis (evaluated by the El Gammal index), corresponding more to a prognostic factor for worsening of the skin-related quality of life. 12 In the current study, similarly only a correlation between pruritus with DLQI was observed.…”

Section: Discussionmentioning

confidence: 99%

Improvement of Quality of Life in Dialysis and Diabetic Patients by Skin Dryness and Pruritus Management with an Ecobiological Dermo-Cosmetic Product

Polena¹,

Chavagnac‐Bonneville²,

Sayag³

2022

CCID

View full text Add to dashboard Cite

Purpose Xerosis and pruritus are common chronic dermatological disorders among dialysis and diabetic patients that are frequently underdiagnosed or neglected, which can impact the quality of life of these patients. This study aimed to evaluate the efficacy and safety of a specific dermo-cosmetic product in the treatment of dry skin and pruritus associated with dialysis and diabetes. Patients and Methods Twenty-nine dialysis patients (mean age 62 years) and 40 diabetic patients (mean age 57 years, 88% type 2) were included in two different single-center open-label uncontrolled clinical trials. All patients presented skin dryness according to the Scaling Roughness Redness and Cracks (SRRC) scale, and pruritus and/or insomnia. They applied the dermo-cosmetic product Medi-Secure Atoderm Xereane (NAOS, Laboratoire Bioderma) once or twice a day. The clinical efficacy (SRRC, pruritus, and insomnia), the skin-related quality of life (Dermatological Life Quality Index, DLQI), and the subjective efficacy were assessed at the inclusion visit and after 28 days of product application, as well as the safety. Results After 28 days of application, the product significantly reduced the SRRC global score of 83% (0.9±0.8 vs 5.1±1.2) and 66% (1.4±1.2 vs 4.2±0.5), pruritus intensity of 76% (1.1±1.3 vs 4.6±2.1) and 78% (0.9±1.7 vs 4.2±2.6), and insomnia intensity of 61% (0.9±1.3 vs 2.4±2.3) and 82% (0.9±1.7 vs 4.8±2.7) in dialysis and diabetic patients, respectively. Furthermore, the product’s application led to an improvement of the skin-related quality of life of 50% (5.4 vs 2.7; p<0.0001) in dialysis patients and 71% (6.6 vs 1.9; p<0.0001) in diabetic patients at D28. In addition, the product was greatly appreciated by all patients for its soothing, comforting, repairing, nourishing, and hydrating effects and was very well tolerated by the entire panels. Conclusion This specific dermo-cosmetic product significantly reduces skin dryness, pruritus, and insomnia in dialysis and diabetic patients, thereby greatly improves their skin-related quality of life. By managing and avoiding bothersome symptoms associated with their disease or treatment, this ecobiological dermo-cosmetic can prevent serious complications that constitute a substantial burden on their daily life.

show abstract

“…72 In studies that measure skin dryness/skin hydration as one of the outcomes, these various topical forms (gels, creams, emulsions, lotions, and solutions) can also reduce skin dryness or improve skin hydration. 68,70,75,76,78,80,84,85,87 Topical drug preparations consist of active ingredients (drugs) in a base (vehicle), and excipients (e.g., emulsifiers, antioxidants, and preservatives). 65,88 A good topical drug preparation contains a composition of basic ingredients that can improve the function of the epidermal barrier.…”

Section: Topical Treatmentmentioning

confidence: 99%

“…However, almost all active ingredients used as topical treatment in these studies were shown to significantly reduce pruritus intensity, except Tacrolimus ointment 0.1% 69 and Dead Sea (DS) minerals 72 . In studies that measure skin dryness/skin hydration as one of the outcomes, these various topical forms (gels, creams, emulsions, lotions, and solutions) can also reduce skin dryness or improve skin hydration 68,70,75,76,78,80,84,85,87 …”

Section: Treatmentmentioning

confidence: 99%

Chronic kidney disease‐associated pruritus in patients undergoing hemodialysis: Xerosis and topical therapy

Krismi

Danarti

Setiabudi

et al. 2023

Hemodialysis International

View full text Add to dashboard Cite

Chronic kidney disease‐associated pruritus (CKD‐aP) is a common and distressing symptom for patients with CKD and a difficult challenge for nephrologists and dermatologists. Recent results showed the multifactorial nature of the pathophysiology, and therapeutic trials were only successful in certain subsets of patients. The clinical manifestations are varied, with xerosis being the most common dermatological manifestation and correlated with the intensity of CKD‐aP. A better understanding of the pathophysiology of xerosis in CKD‐aP and appropriate topical treatment could correct xerosis to reduce the intensity of CKD‐aP and improve the patient's quality of life.

show abstract

Efficacy of a moisturizer for pruritus accompanied by xerosis in patients undergoing dialysis: A multicenter, open‐label, randomized verification study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 6 publications

References 12 publications

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream for Non-Exudative Eczema: A Systematic Review and Meta-Analysis

Efficacy and Safety of Mucopolysaccharide Polysulfate Cream for Non-Exudative Eczema: A Systematic Review and Meta-Analysis

Improvement of Quality of Life in Dialysis and Diabetic Patients by Skin Dryness and Pruritus Management with an Ecobiological Dermo-Cosmetic Product

Chronic kidney disease‐associated pruritus in patients undergoing hemodialysis: Xerosis and topical therapy

Contact Info

Product

Resources

About